Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 31 entries
Sorted by: Best Match Show Resources per page
Exploration of the chondrosarcoma metabolome; the mTOR pathway as an important pro-survival pathway.

Journal of bone oncology

Addie RD, de Jong Y, Alberti G, Kruisselbrink AB, Que I, Baelde H, Bovée JVMG.
PMID: 30766792
J Bone Oncol. 2019 Jan 29;15:100222. doi: 10.1016/j.jbo.2019.100222. eCollection 2019 Apr.

BACKGROUND: Chondrosarcomas are malignant cartilage-producing tumors showing mutations and changes in gene expression in metabolism related genes. In this study, we aimed to explore the metabolome and identify targetable metabolic vulnerabilities in chondrosarcoma.METHODS: A custom-designed metabolic compound screen containing...

Cite
Addie RD, de Jong Y, Alberti G, et al. Exploration of the chondrosarcoma metabolome; the mTOR pathway as an important pro-survival pathway. J Bone Oncol. 2019;15:100222doi: 10.1016/j.jbo.2019.100222.
Addie, R. D., de Jong, Y., Alberti, G., Kruisselbrink, A. B., Que, I., Baelde, H., & Bovée, J. V. M. G. (2019). Exploration of the chondrosarcoma metabolome; the mTOR pathway as an important pro-survival pathway. Journal of bone oncology, 15100222. https://doi.org/10.1016/j.jbo.2019.100222
Addie, Ruben D, et al. "Exploration of the chondrosarcoma metabolome; the mTOR pathway as an important pro-survival pathway." Journal of bone oncology vol. 15 (2019): 100222. doi: https://doi.org/10.1016/j.jbo.2019.100222
Addie RD, de Jong Y, Alberti G, Kruisselbrink AB, Que I, Baelde H, Bovée JVMG. Exploration of the chondrosarcoma metabolome; the mTOR pathway as an important pro-survival pathway. J Bone Oncol. 2019 Jan 29;15:100222. doi: 10.1016/j.jbo.2019.100222. eCollection 2019 Apr. PMID: 30766792; PMCID: PMC6360255.
Copy Download .nbib Format: NLM
Sensitivity to Experiencing Alcohol Hangovers: Reconsideration of the 0.11% Blood Alcohol Concentration (BAC) Threshold for Having a Hangover.

Journal of clinical medicine

Verster JC, Kruisselbrink LD, Slot KA, Anogeianaki A, Adams S, Alford C, Arnoldy L, Ayre E, Balikji S, Benson S, Bruce G, Devenney LE, Frone MR, Gunn C, Heffernan T, Hensel KO, Hogewoning A, Johnson SJ, van Lawick van Pabst AE, van de Loo AJAE, Mackus M, Merlo A, Murphy RJL, Owen L, Palmer EOC, van Rossum CJI, Scholey A, Terpstra C, Vatsalya V, Vermeulen SA, van Wijk M, Stock AK.
PMID: 31936502
J Clin Med. 2020 Jan 09;9(1). doi: 10.3390/jcm9010179.

The 2010 Alcohol Hangover Research Group consensus paper defined a cutoff blood alcohol concentration (BAC) of 0.11% as a toxicological threshold indicating that sufficient alcohol had been consumed to develop a hangover. The cutoff was based on previous research...

Cite
Verster JC, Kruisselbrink LD, Slot KA, et al. Sensitivity to Experiencing Alcohol Hangovers: Reconsideration of the 0.11% Blood Alcohol Concentration (BAC) Threshold for Having a Hangover. J Clin Med. 2020;9(1)doi: 10.3390/jcm9010179.
Verster, J. C., Kruisselbrink, L. D., Slot, K. A., Anogeianaki, A., Adams, S., Alford, C., Arnoldy, L., Ayre, E., Balikji, S., Benson, S., Bruce, G., Devenney, L. E., Frone, M. R., Gunn, C., Heffernan, T., Hensel, K. O., Hogewoning, A., Johnson, S. J., van Lawick van Pabst, A. E., van de Loo, A. J. A. E., Mackus, M., Merlo, A., Murphy, R. J. L., Owen, L., Palmer, E. O. C., van Rossum, C. J. I., Scholey, A., Terpstra, C., Vatsalya, V., Vermeulen, S. A., van Wijk, M., & Stock, A. K. (2020). Sensitivity to Experiencing Alcohol Hangovers: Reconsideration of the 0.11% Blood Alcohol Concentration (BAC) Threshold for Having a Hangover. Journal of clinical medicine, 9(1), . https://doi.org/10.3390/jcm9010179
Verster, Joris C, et al. "Sensitivity to Experiencing Alcohol Hangovers: Reconsideration of the 0.11% Blood Alcohol Concentration (BAC) Threshold for Having a Hangover." Journal of clinical medicine vol. 9,1 (2020). doi: https://doi.org/10.3390/jcm9010179
Verster JC, Kruisselbrink LD, Slot KA, Anogeianaki A, Adams S, Alford C, Arnoldy L, Ayre E, Balikji S, Benson S, Bruce G, Devenney LE, Frone MR, Gunn C, Heffernan T, Hensel KO, Hogewoning A, Johnson SJ, van Lawick van Pabst AE, van de Loo AJAE, Mackus M, Merlo A, Murphy RJL, Owen L, Palmer EOC, van Rossum CJI, Scholey A, Terpstra C, Vatsalya V, Vermeulen SA, van Wijk M, Stock AK. Sensitivity to Experiencing Alcohol Hangovers: Reconsideration of the 0.11% Blood Alcohol Concentration (BAC) Threshold for Having a Hangover. J Clin Med. 2020 Jan 09;9(1). doi: 10.3390/jcm9010179. PMID: 31936502; PMCID: PMC7019760.
Copy Download .nbib Format: NLM
Radiotherapy resistance in chondrosarcoma cells; a possible correlation with alterations in cell cycle related genes.

Clinical sarcoma research

de Jong Y, Ingola M, Briaire-de Bruijn IH, Kruisselbrink AB, Venneker S, Palubeckaite I, Heijs BPAM, Cleton-Jansen AM, Haas RLM, Bovée JVMG.
PMID: 31160965
Clin Sarcoma Res. 2019 May 28;9:9. doi: 10.1186/s13569-019-0119-0. eCollection 2019.

BACKGROUND: Conventional chondrosarcomas are malignant cartilage tumors considered radioresistant. Nevertheless, retrospective series show a small but significant survival benefit for patients with locally advanced disease treated with radiotherapy. And, in daily practice when considered inoperable their irradiation is an...

Cite
de Jong Y, Ingola M, Briaire-de Bruijn IH, et al. Radiotherapy resistance in chondrosarcoma cells; a possible correlation with alterations in cell cycle related genes. Clin Sarcoma Res. 2019;9:9doi: 10.1186/s13569-019-0119-0.
de Jong, Y., Ingola, M., Briaire-de Bruijn, I. H., Kruisselbrink, A. B., Venneker, S., Palubeckaite, I., Heijs, B. P. A. M., Cleton-Jansen, A. M., Haas, R. L. M., & Bovée, J. V. M. G. (2019). Radiotherapy resistance in chondrosarcoma cells; a possible correlation with alterations in cell cycle related genes. Clinical sarcoma research, 99. https://doi.org/10.1186/s13569-019-0119-0
de Jong, Yvonne, et al. "Radiotherapy resistance in chondrosarcoma cells; a possible correlation with alterations in cell cycle related genes." Clinical sarcoma research vol. 9 (2019): 9. doi: https://doi.org/10.1186/s13569-019-0119-0
de Jong Y, Ingola M, Briaire-de Bruijn IH, Kruisselbrink AB, Venneker S, Palubeckaite I, Heijs BPAM, Cleton-Jansen AM, Haas RLM, Bovée JVMG. Radiotherapy resistance in chondrosarcoma cells; a possible correlation with alterations in cell cycle related genes. Clin Sarcoma Res. 2019 May 28;9:9. doi: 10.1186/s13569-019-0119-0. eCollection 2019. PMID: 31160965; PMCID: PMC6540537.
Copy Download .nbib Format: NLM
White Paper on Early Critical Care Services in Low Resource Settings.

Annals of global health

Losonczy LI, Papali A, Kivlehan S, Calvello Hynes EJ, Calderon G, Laytin A, Moll V, Al Hazmi A, Alsabri M, Aryal D, Atua V, Becker T, Benzoni N, Dippenaar E, Duneant E, Girma B, George N, Gupta P, Jaung M, Hollong B, Kabongo D, Kruisselbrink RJ, Lee D, Maldonado A, May J, Osei-Ampofo M, Osman YO, Owoo C, Rouhani SA, Sawe H, Schnorr D, Shrestha GS, Sohoni A, Sultan M, Tenner AG, Yusuf H, Adhikari NK, Murthy S, Kissoon N, Marshall J, Khoury A, Bellou A, Wallis L, Reynolds T.
PMID: 34786353
Ann Glob Health. 2021 Nov 03;87(1):105. doi: 10.5334/aogh.3377. eCollection 2021.

This White Paper has been formally accepted for support by the International Federation for Emergency Medicine (IFEM) and by the World Federation of Intensive and Critical Care (WFICC), put forth by a multi-specialty group of intensivists and emergency medicine...

Cite
Losonczy LI, Papali A, Kivlehan S, et al. White Paper on Early Critical Care Services in Low Resource Settings. Ann Glob Health. 2021;87(1):105doi: 10.5334/aogh.3377.
Losonczy, L. I., Papali, A., Kivlehan, S., Calvello Hynes, E. J., Calderon, G., Laytin, A., Moll, V., Al Hazmi, A., Alsabri, M., Aryal, D., Atua, V., Becker, T., Benzoni, N., Dippenaar, E., Duneant, E., Girma, B., George, N., Gupta, P., Jaung, M., Hollong, B., Kabongo, D., Kruisselbrink, R. J., Lee, D., Maldonado, A., May, J., Osei-Ampofo, M., Osman, Y. O., Owoo, C., Rouhani, S. A., Sawe, H., Schnorr, D., Shrestha, G. S., Sohoni, A., Sultan, M., Tenner, A. G., Yusuf, H., Adhikari, N. K., Murthy, S., Kissoon, N., Marshall, J., Khoury, A., Bellou, A., Wallis, L., & Reynolds, T. (2021). White Paper on Early Critical Care Services in Low Resource Settings. Annals of global health, 87(1), 105. https://doi.org/10.5334/aogh.3377
Losonczy, Lia I, et al. "White Paper on Early Critical Care Services in Low Resource Settings." Annals of global health vol. 87,1 (2021): 105. doi: https://doi.org/10.5334/aogh.3377
Losonczy LI, Papali A, Kivlehan S, Calvello Hynes EJ, Calderon G, Laytin A, Moll V, Al Hazmi A, Alsabri M, Aryal D, Atua V, Becker T, Benzoni N, Dippenaar E, Duneant E, Girma B, George N, Gupta P, Jaung M, Hollong B, Kabongo D, Kruisselbrink RJ, Lee D, Maldonado A, May J, Osei-Ampofo M, Osman YO, Owoo C, Rouhani SA, Sawe H, Schnorr D, Shrestha GS, Sohoni A, Sultan M, Tenner AG, Yusuf H, Adhikari NK, Murthy S, Kissoon N, Marshall J, Khoury A, Bellou A, Wallis L, Reynolds T. White Paper on Early Critical Care Services in Low Resource Settings. Ann Glob Health. 2021 Nov 03;87(1):105. doi: 10.5334/aogh.3377. eCollection 2021. PMID: 34786353; PMCID: PMC8570193.
Copy Download .nbib Format: NLM
Genomics Integration Into Nephrology Practice.

Kidney medicine

Pinto E Vairo F, Prochnow C, Kemppainen JL, Lisi EC, Steyermark JM, Kruisselbrink TM, Pichurin PN, Dhamija R, Hager MM, Albadri S, Cornell LD, Lazaridis KN, Klee EW, Senum SR, El Ters M, Amer H, Baudhuin LM, Moyer AM, Keddis MT, Zand L, Sas DJ, Erickson SB, Fervenza FC, Lieske JC, Harris PC, Hogan MC.
PMID: 34746741
Kidney Med. 2021 Jun 29;3(5):785-798. doi: 10.1016/j.xkme.2021.04.014. eCollection 2021.

RATIONALE & OBJECTIVE: The etiology of kidney disease remains unknown in many individuals with chronic kidney disease (CKD). We created the Mayo Clinic Nephrology Genomics Clinic to improve our ability to integrate genomic and clinical data to identify the...

Cite
Pinto E Vairo F, Prochnow C, Kemppainen JL, et al. Genomics Integration Into Nephrology Practice. Kidney Med. 2021;3(5):785-798doi: 10.1016/j.xkme.2021.04.014.
Pinto E Vairo, F., Prochnow, C., Kemppainen, J. L., Lisi, E. C., Steyermark, J. M., Kruisselbrink, T. M., Pichurin, P. N., Dhamija, R., Hager, M. M., Albadri, S., Cornell, L. D., Lazaridis, K. N., Klee, E. W., Senum, S. R., El Ters, M., Amer, H., Baudhuin, L. M., Moyer, A. M., Keddis, M. T., Zand, L., Sas, D. J., Erickson, S. B., Fervenza, F. C., Lieske, J. C., Harris, P. C., & Hogan, M. C. (2021). Genomics Integration Into Nephrology Practice. Kidney medicine, 3(5), 785-798. https://doi.org/10.1016/j.xkme.2021.04.014
Pinto E Vairo, Filippo, et al. "Genomics Integration Into Nephrology Practice." Kidney medicine vol. 3,5 (2021): 785-798. doi: https://doi.org/10.1016/j.xkme.2021.04.014
Pinto E Vairo F, Prochnow C, Kemppainen JL, Lisi EC, Steyermark JM, Kruisselbrink TM, Pichurin PN, Dhamija R, Hager MM, Albadri S, Cornell LD, Lazaridis KN, Klee EW, Senum SR, El Ters M, Amer H, Baudhuin LM, Moyer AM, Keddis MT, Zand L, Sas DJ, Erickson SB, Fervenza FC, Lieske JC, Harris PC, Hogan MC. Genomics Integration Into Nephrology Practice. Kidney Med. 2021 Jun 29;3(5):785-798. doi: 10.1016/j.xkme.2021.04.014. eCollection 2021. PMID: 34746741; PMCID: PMC8551494.
Copy Download .nbib Format: NLM
Protocol for Application, Standardization and Validation of the Forskolin-Induced Swelling Assay in Cystic Fibrosis Human Colon Organoids.

STAR protocols

Vonk AM, van Mourik P, Ramalho AS, Silva IAL, Statia M, Kruisselbrink E, Suen SWF, Dekkers JF, Vleggaar FP, Houwen RHJ, Mullenders J, Boj SF, Vries R, Amaral MD, de Boeck K, van der Ent CK, Beekman JM.
PMID: 33111074
STAR Protoc. 2020 Jun 03;1(1):100019. doi: 10.1016/j.xpro.2020.100019. eCollection 2020 Jun 19.

This protocol describes the isolation, handling, culture of, and experiments with human colon stem cell organoids in the context of cystic fibrosis (CF). In human colon organoids, the function of cystic fibrosis transmembrane conductance regulator (CFTR) protein and its...

Cite
Vonk AM, van Mourik P, Ramalho AS, et al. Protocol for Application, Standardization and Validation of the Forskolin-Induced Swelling Assay in Cystic Fibrosis Human Colon Organoids. STAR Protoc. 2020;1(1):100019doi: 10.1016/j.xpro.2020.100019.
Vonk, A. M., van Mourik, P., Ramalho, A. S., Silva, I. A. L., Statia, M., Kruisselbrink, E., Suen, S. W. F., Dekkers, J. F., Vleggaar, F. P., Houwen, R. H. J., Mullenders, J., Boj, S. F., Vries, R., Amaral, M. D., de Boeck, K., van der Ent, C. K., & Beekman, J. M. (2020). Protocol for Application, Standardization and Validation of the Forskolin-Induced Swelling Assay in Cystic Fibrosis Human Colon Organoids. STAR protocols, 1(1), 100019. https://doi.org/10.1016/j.xpro.2020.100019
Vonk, Annelotte M, et al. "Protocol for Application, Standardization and Validation of the Forskolin-Induced Swelling Assay in Cystic Fibrosis Human Colon Organoids." STAR protocols vol. 1,1 (2020): 100019. doi: https://doi.org/10.1016/j.xpro.2020.100019
Vonk AM, van Mourik P, Ramalho AS, Silva IAL, Statia M, Kruisselbrink E, Suen SWF, Dekkers JF, Vleggaar FP, Houwen RHJ, Mullenders J, Boj SF, Vries R, Amaral MD, de Boeck K, van der Ent CK, Beekman JM. Protocol for Application, Standardization and Validation of the Forskolin-Induced Swelling Assay in Cystic Fibrosis Human Colon Organoids. STAR Protoc. 2020 Jun 03;1(1):100019. doi: 10.1016/j.xpro.2020.100019. eCollection 2020 Jun 19. PMID: 33111074; PMCID: PMC7580120.
Copy Download .nbib Format: NLM
Targeting survivin as a potential new treatment for chondrosarcoma of bone.

Oncogenesis

de Jong Y, van Oosterwijk JG, Kruisselbrink AB, Briaire-de Bruijn IH, Agrogiannis G, Baranski Z, Cleven AH, Cleton-Jansen AM, van de Water B, Danen EH, Bovée JV.
PMID: 27159675
Oncogenesis. 2016 May 09;5:e222. doi: 10.1038/oncsis.2016.33.

Chondrosarcomas are malignant cartilage-forming bone tumors, which are intrinsically resistant to chemo- and radiotherapy, leaving surgical removal as the only curative treatment option. Therefore, our aim was to identify genes involved in chondrosarcoma cell survival that could serve as...

Cite
de Jong Y, van Oosterwijk JG, Kruisselbrink AB, et al. Targeting survivin as a potential new treatment for chondrosarcoma of bone. Oncogenesis. 2016;5:e222doi: 10.1038/oncsis.2016.33.
de Jong, Y., van Oosterwijk, J. G., Kruisselbrink, A. B., Briaire-de Bruijn, I. H., Agrogiannis, G., Baranski, Z., Cleven, A. H., Cleton-Jansen, A. M., van de Water, B., Danen, E. H., & Bovée, J. V. (2016). Targeting survivin as a potential new treatment for chondrosarcoma of bone. Oncogenesis, 5e222. https://doi.org/10.1038/oncsis.2016.33
de Jong, Y, et al. "Targeting survivin as a potential new treatment for chondrosarcoma of bone." Oncogenesis vol. 5 (2016): e222. doi: https://doi.org/10.1038/oncsis.2016.33
de Jong Y, van Oosterwijk JG, Kruisselbrink AB, Briaire-de Bruijn IH, Agrogiannis G, Baranski Z, Cleven AH, Cleton-Jansen AM, van de Water B, Danen EH, Bovée JV. Targeting survivin as a potential new treatment for chondrosarcoma of bone. Oncogenesis. 2016 May 09;5:e222. doi: 10.1038/oncsis.2016.33. PMID: 27159675; PMCID: PMC4945750.
Copy Download .nbib Format: NLM
Transformed Canine and Murine Mesenchymal Stem Cells as a Model for Sarcoma with Complex Genomics.

Cancers

Franceschini N, Verbruggen B, Tryfonidou MA, Kruisselbrink AB, Baelde H, de Visser KE, Szuhai K, Cleton-Jansen AM, Bovée JVMG.
PMID: 33807947
Cancers (Basel). 2021 Mar 05;13(5). doi: 10.3390/cancers13051126.

Sarcomas are rare mesenchymal tumors with a broad histological spectrum, but they can be divided into two groups based on molecular pathology: sarcomas with simple or complex genomics. Tumors with complex genomics can have aneuploidy and copy number gains...

Cite
Franceschini N, Verbruggen B, Tryfonidou MA, et al. Transformed Canine and Murine Mesenchymal Stem Cells as a Model for Sarcoma with Complex Genomics. Cancers (Basel). 2021;13(5)doi: 10.3390/cancers13051126.
Franceschini, N., Verbruggen, B., Tryfonidou, M. A., Kruisselbrink, A. B., Baelde, H., de Visser, K. E., Szuhai, K., Cleton-Jansen, A. M., & Bovée, J. V. M. G. (2021). Transformed Canine and Murine Mesenchymal Stem Cells as a Model for Sarcoma with Complex Genomics. Cancers, 13(5), . https://doi.org/10.3390/cancers13051126
Franceschini, Natasja, et al. "Transformed Canine and Murine Mesenchymal Stem Cells as a Model for Sarcoma with Complex Genomics." Cancers vol. 13,5 (2021). doi: https://doi.org/10.3390/cancers13051126
Franceschini N, Verbruggen B, Tryfonidou MA, Kruisselbrink AB, Baelde H, de Visser KE, Szuhai K, Cleton-Jansen AM, Bovée JVMG. Transformed Canine and Murine Mesenchymal Stem Cells as a Model for Sarcoma with Complex Genomics. Cancers (Basel). 2021 Mar 05;13(5). doi: 10.3390/cancers13051126. PMID: 33807947; PMCID: PMC7961539.
Copy Download .nbib Format: NLM
A murine mesenchymal stem cell model for initiating events in osteosarcomagenesis points to CDK4/CDK6 inhibition as a therapeutic target.

Laboratory investigation; a journal of technical methods and pathology

Franceschini N, Gaeta R, Krimpenfort P, Briaire-de Bruijn I, Kruisselbrink AB, Szuhai K, Palubeckaitė I, Cleton-Jansen AM, Bovée JVMG.
PMID: 34921235
Lab Invest. 2021 Dec 17; doi: 10.1038/s41374-021-00709-z. Epub 2021 Dec 17.

Osteosarcoma is a high-grade bone-forming neoplasm, with a complex genome. Tumours frequently show chromothripsis, many deletions, translocations and copy number alterations. Alterations in the p53 or Rb pathway are the most common genetic alterations identified in osteosarcoma. Using spontaneously...

Cite
Franceschini N, Gaeta R, Krimpenfort P, et al. A murine mesenchymal stem cell model for initiating events in osteosarcomagenesis points to CDK4/CDK6 inhibition as a therapeutic target. Lab Invest. 2021;doi: 10.1038/s41374-021-00709-z.
Franceschini, N., Gaeta, R., Krimpenfort, P., Briaire-de Bruijn, I., Kruisselbrink, A. B., Szuhai, K., Palubeckaitė, I., Cleton-Jansen, A. M., & Bovée, J. V. M. G. (2021). A murine mesenchymal stem cell model for initiating events in osteosarcomagenesis points to CDK4/CDK6 inhibition as a therapeutic target. Laboratory investigation; a journal of technical methods and pathology, . https://doi.org/10.1038/s41374-021-00709-z
Franceschini, Natasja, et al. "A murine mesenchymal stem cell model for initiating events in osteosarcomagenesis points to CDK4/CDK6 inhibition as a therapeutic target." Laboratory investigation; a journal of technical methods and pathology vol. (2021). doi: https://doi.org/10.1038/s41374-021-00709-z
Franceschini N, Gaeta R, Krimpenfort P, Briaire-de Bruijn I, Kruisselbrink AB, Szuhai K, Palubeckaitė I, Cleton-Jansen AM, Bovée JVMG. A murine mesenchymal stem cell model for initiating events in osteosarcomagenesis points to CDK4/CDK6 inhibition as a therapeutic target. Lab Invest. 2021 Dec 17; doi: 10.1038/s41374-021-00709-z. Epub 2021 Dec 17. PMID: 34921235.
Copy Download .nbib Format: NLM
A murine mesenchymal stem cell model for initiating events in osteosarcomagenesis points to CDK4/CDK6 inhibition as a therapeutic target.

Laboratory investigation; a journal of technical methods and pathology

Franceschini N, Gaeta R, Krimpenfort P, Briaire-de Bruijn I, Kruisselbrink AB, Szuhai K, Palubeckaitė I, Cleton-Jansen AM, Bovée JVMG.
PMID: 34921235
Lab Invest. 2021 Dec 17; doi: 10.1038/s41374-021-00709-z. Epub 2021 Dec 17.

Osteosarcoma is a high-grade bone-forming neoplasm, with a complex genome. Tumours frequently show chromothripsis, many deletions, translocations and copy number alterations. Alterations in the p53 or Rb pathway are the most common genetic alterations identified in osteosarcoma. Using spontaneously...

Cite
Franceschini N, Gaeta R, Krimpenfort P, et al. A murine mesenchymal stem cell model for initiating events in osteosarcomagenesis points to CDK4/CDK6 inhibition as a therapeutic target. Lab Invest. 2021;doi: 10.1038/s41374-021-00709-z.
Franceschini, N., Gaeta, R., Krimpenfort, P., Briaire-de Bruijn, I., Kruisselbrink, A. B., Szuhai, K., Palubeckaitė, I., Cleton-Jansen, A. M., & Bovée, J. V. M. G. (2021). A murine mesenchymal stem cell model for initiating events in osteosarcomagenesis points to CDK4/CDK6 inhibition as a therapeutic target. Laboratory investigation; a journal of technical methods and pathology, . https://doi.org/10.1038/s41374-021-00709-z
Franceschini, Natasja, et al. "A murine mesenchymal stem cell model for initiating events in osteosarcomagenesis points to CDK4/CDK6 inhibition as a therapeutic target." Laboratory investigation; a journal of technical methods and pathology vol. (2021). doi: https://doi.org/10.1038/s41374-021-00709-z
Franceschini N, Gaeta R, Krimpenfort P, Briaire-de Bruijn I, Kruisselbrink AB, Szuhai K, Palubeckaitė I, Cleton-Jansen AM, Bovée JVMG. A murine mesenchymal stem cell model for initiating events in osteosarcomagenesis points to CDK4/CDK6 inhibition as a therapeutic target. Lab Invest. 2021 Dec 17; doi: 10.1038/s41374-021-00709-z. Epub 2021 Dec 17. PMID: 34921235.
Copy Download .nbib Format: NLM
American Society of Regional Anesthesia and Pain Medicine expert panel recommendations on point-of-care ultrasound education and training for regional anesthesiologists and pain physicians-part I: clinical indications.

Regional anesthesia and pain medicine

Haskins SC, Bronshteyn Y, Perlas A, El-Boghdadly K, Zimmerman J, Silva M, Boretsky K, Chan V, Kruisselbrink R, Byrne M, Hernandez N, Boublik J, Manson WC, Hogg R, Wilkinson JN, Kalagara H, Nejim J, Ramsingh D, Shankar H, Nader A, Souza D, Narouze S.
PMID: 33632778
Reg Anesth Pain Med. 2021 Dec;46(12):1031-1047. doi: 10.1136/rapm-2021-102560. Epub 2021 Feb 24.

Point-of-care ultrasound (POCUS) is a critical skill for all regional anesthesiologists and pain physicians to help diagnose relevant complications related to routine practice and guide perioperative management. In an effort to inform the regional anesthesia and pain community as...

Cite
Haskins SC, Bronshteyn Y, Perlas A, et al. American Society of Regional Anesthesia and Pain Medicine expert panel recommendations on point-of-care ultrasound education and training for regional anesthesiologists and pain physicians-part I: clinical indications. Reg Anesth Pain Med. 2021;46(12):1031-1047doi: 10.1136/rapm-2021-102560.
Haskins, S. C., Bronshteyn, Y., Perlas, A., El-Boghdadly, K., Zimmerman, J., Silva, M., Boretsky, K., Chan, V., Kruisselbrink, R., Byrne, M., Hernandez, N., Boublik, J., Manson, W. C., Hogg, R., Wilkinson, J. N., Kalagara, H., Nejim, J., Ramsingh, D., Shankar, H., Nader, A., Souza, D., & Narouze, S. (2021). American Society of Regional Anesthesia and Pain Medicine expert panel recommendations on point-of-care ultrasound education and training for regional anesthesiologists and pain physicians-part I: clinical indications. Regional anesthesia and pain medicine, 46(12), 1031-1047. https://doi.org/10.1136/rapm-2021-102560
Haskins, Stephen C, et al. "American Society of Regional Anesthesia and Pain Medicine expert panel recommendations on point-of-care ultrasound education and training for regional anesthesiologists and pain physicians-part I: clinical indications." Regional anesthesia and pain medicine vol. 46,12 (2021): 1031-1047. doi: https://doi.org/10.1136/rapm-2021-102560
Haskins SC, Bronshteyn Y, Perlas A, El-Boghdadly K, Zimmerman J, Silva M, Boretsky K, Chan V, Kruisselbrink R, Byrne M, Hernandez N, Boublik J, Manson WC, Hogg R, Wilkinson JN, Kalagara H, Nejim J, Ramsingh D, Shankar H, Nader A, Souza D, Narouze S. American Society of Regional Anesthesia and Pain Medicine expert panel recommendations on point-of-care ultrasound education and training for regional anesthesiologists and pain physicians-part I: clinical indications. Reg Anesth Pain Med. 2021 Dec;46(12):1031-1047. doi: 10.1136/rapm-2021-102560. Epub 2021 Feb 24. PMID: 33632778.
Copy Download .nbib Format: NLM
SUMOylation Is Associated with Aggressive Behavior in Chondrosarcoma of Bone.

Cancers

Kroonen JS, Kruisselbrink AB, Briaire-de Bruijn IH, Olaofe OO, Bovée JVMG, Vertegaal ACO.
PMID: 34359724
Cancers (Basel). 2021 Jul 29;13(15). doi: 10.3390/cancers13153823.

Multiple components of the SUMOylation machinery are deregulated in various cancers and could represent potential therapeutic targets. Understanding the role of SUMOylation in tumor progression and aggressiveness would increase our insight in the role of SUMO in cancer and...

Cite
Kroonen JS, Kruisselbrink AB, Briaire-de Bruijn IH, et al. SUMOylation Is Associated with Aggressive Behavior in Chondrosarcoma of Bone. Cancers (Basel). 2021;13(15)doi: 10.3390/cancers13153823.
Kroonen, J. S., Kruisselbrink, A. B., Briaire-de Bruijn, I. H., Olaofe, O. O., Bovée, J. V. M. G., & Vertegaal, A. C. O. (2021). SUMOylation Is Associated with Aggressive Behavior in Chondrosarcoma of Bone. Cancers, 13(15), . https://doi.org/10.3390/cancers13153823
Kroonen, Jessie S, et al. "SUMOylation Is Associated with Aggressive Behavior in Chondrosarcoma of Bone." Cancers vol. 13,15 (2021). doi: https://doi.org/10.3390/cancers13153823
Kroonen JS, Kruisselbrink AB, Briaire-de Bruijn IH, Olaofe OO, Bovée JVMG, Vertegaal ACO. SUMOylation Is Associated with Aggressive Behavior in Chondrosarcoma of Bone. Cancers (Basel). 2021 Jul 29;13(15). doi: 10.3390/cancers13153823. PMID: 34359724; PMCID: PMC8345166.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 31 entries